drugset / Trial / NCT02405260
Add Glucokinase Activator to Target A1c
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
Timeline
- Start
- 2015-03
- Primary completion
- 2016-07
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadisegliatin | Small molecule | 400 mg | — |
| Subject | Cadisegliatin | Small molecule | 800 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |